Cardiovascular and Metabolic Disease: New Treatment and Future Directions
The present Special Issue will lead you to discover the association between cardiovascular and metabolic diseases, through update reviews and original articles exploring the pathophysiological mechanisms underpinning this association and describing the latest results in term of cardiovascular event...
Kaydedildi:
| Diğer Yazarlar: | , |
|---|---|
| Materyal Türü: | Elektronik Kitap Bölümü |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Konular: | |
| Online Erişim: | DOAB: download the publication DOAB: description of the publication |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_101317 | ||
| 005 | 20230714 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230714s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-7878-1 | ||
| 020 | |a 9783036578798 | ||
| 020 | |a 9783036578781 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-7878-1 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MMG |2 bicssc | |
| 100 | 1 | |a Caturano, Alfredo |4 edt | |
| 700 | 1 | |a Galiero, Raffaele |4 edt | |
| 700 | 1 | |a Caturano, Alfredo |4 oth | |
| 700 | 1 | |a Galiero, Raffaele |4 oth | |
| 245 | 1 | 0 | |a Cardiovascular and Metabolic Disease: New Treatment and Future Directions |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (210 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The present Special Issue will lead you to discover the association between cardiovascular and metabolic diseases, through update reviews and original articles exploring the pathophysiological mechanisms underpinning this association and describing the latest results in term of cardiovascular event prevention. An interesting scientific journey that reflects the recent advances in pharmacological treatments and interventional procedures. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a low-density lipoprotein receptor | ||
| 653 | |a apolipoprotein E | ||
| 653 | |a hyperglycemia | ||
| 653 | |a type 2 diabetes | ||
| 653 | |a Western diet | ||
| 653 | |a diabetes mellitus | ||
| 653 | |a GPCRs | ||
| 653 | |a GPR26 | ||
| 653 | |a monocytes | ||
| 653 | |a peripheral blood cells | ||
| 653 | |a metabolomics | ||
| 653 | |a diabetes | ||
| 653 | |a N-Acetyl asparagine | ||
| 653 | |a QTc | ||
| 653 | |a cardiac fibrosis | ||
| 653 | |a scar tissue | ||
| 653 | |a anti-fibrotic therapies | ||
| 653 | |a cardiovascular diseases | ||
| 653 | |a myofibroblasts | ||
| 653 | |a nitric oxide synthase uncoupling | ||
| 653 | |a sapropterin | ||
| 653 | |a diabetic nephropathy | ||
| 653 | |a atrial fibrillation | ||
| 653 | |a hyperthyroidism | ||
| 653 | |a warfarin | ||
| 653 | |a ischemic stroke | ||
| 653 | |a transient ischemic attack | ||
| 653 | |a transplant | ||
| 653 | |a complications | ||
| 653 | |a mortality | ||
| 653 | |a outcome | ||
| 653 | |a glucose metabolism | ||
| 653 | |a body mass index | ||
| 653 | |a metabolic syndrome | ||
| 653 | |a breast arterial calcifications | ||
| 653 | |a cardiovascular risk | ||
| 653 | |a mammograms | ||
| 653 | |a risk assessment | ||
| 653 | |a prevention | ||
| 653 | |a cost effectiveness | ||
| 653 | |a cardiac autonomic neuropathy | ||
| 653 | |a oxidative stress | ||
| 653 | |a inflammation | ||
| 653 | |a endothelium dysfunction | ||
| 653 | |a direct oral anticoagulant | ||
| 653 | |a stroke prevention | ||
| 653 | |a elderly | ||
| 653 | |a frail | ||
| 653 | |a malignancy | ||
| 653 | |a extreme weight | ||
| 653 | |a bioprosthetic valve | ||
| 653 | |a endocannabinoid system | ||
| 653 | |a CB1 cannabinoid receptor | ||
| 653 | |a metabolic disease | ||
| 653 | |a non-alcoholic fatty liver disease | ||
| 653 | |a sodium-glucose cotransporter inhibitors | ||
| 653 | |a metformin | ||
| 653 | |a FibroScan® | ||
| 653 | |a controlled attenuation parameter | ||
| 653 | |a type 2 diabetes mellitus | ||
| 653 | |a heart failure | ||
| 653 | |a hemodynamics | ||
| 653 | |a dapagliflosin | ||
| 653 | |a adropin | ||
| 653 | |a natriuretic peptide | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7411 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/101317 |7 0 |z DOAB: description of the publication |